Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Ofloxacin Stories

2014-03-24 08:29:42

FAIRFIELD, N.J., March 24, 2014 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced today a licensing agreement with Ferrer, a privately-held Spanish pharmaceutical company, for the commercialization rights to Ozenoxacin 1% Cream in the United States. Ozenoxacin is a novel, bactericidal non-fluorinated quinolone in development as a topical treatment for impetigo. In 2013, Ferrer successfully completed the first Phase III Clinical Trial of Ozenoxacin in adult and pediatric...

2014-03-13 04:23:04

TAIPEI, March 13, 2014 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that the Taiwan Food and Drug Administration (TFDA) has approved the new drug application (NDA) of Taigexyn(® )(nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn(®). An NDA for Taigexyn(® ) was also submitted to China FDA (CFDA) in...

2014-02-20 23:23:30

Drug Allegedly Linked to Serious Muscle Problems and Nerve Damage Dallas, TX (PRWEB) February 20, 2014 The national law firm of Baron and Budd is now representing clients filing lawsuits against the maker of Cipro, an antibiotic that has been allegedly linked to nerve damage and peripheral neuropathy. This is a muscle condition that can lead to several problems, including difficulty walking, significant pain and arm and leg numbness. Cipro, the brand name for the drug ciprofloxacin, is...

2014-02-20 23:01:06

Antibiotic Allegedly Associated With Severe Nerve and Muscle Problems Dallas, TX (PRWEB) February 20, 2014 Baron and Budd, a national plaintiffs’ law firm, announced today that it is accepting lawsuits against the manufacturers of Levaquin, an antibiotic designed to treat bacterial illnesses and infections. The medication has been allegedly linked to a serious condition known as peripheral neuropathy, which can result in several types of sensory problems such as pain, diminished...

2013-12-23 04:20:43

TAIPEI, Dec. 23, 2013 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that the U.S. Food and Drug Administration (FDA) has granted nemonoxacin (Taigexyn(®)) Qualified Infectious Disease Product (QIDP) and Fast Track designations for community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSI). These two designations should enable TaiGen and/or its partners to benefit from certain incentives for the...

2013-11-27 15:08:04

In contrast to findings of a recent study, researchers in Denmark did not find an association between use of a class of antibiotics known as fluoroquinolones (such as ciprofloxacin) and an increased risk of retinal detachment, according to a study appearing in the November 27 issue of JAMA. Retinal detachment (a separation of the retina from its connection at the back of the eye) is an acute eye disorder that may lead to loss of vision despite prompt surgical intervention. A recent study...

2013-09-05 16:25:42

Data presented on results in healthy and infected animals, survival in combination with antibiotics, and development of adaptive immunity PINE BROOK, N.J. and VICTORIA, British Columbia, Sept. 5, 2013 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented key findings from nonclinical studies evaluating the company's anthrax anti-toxin therapy, ETI-204 (Anthim), at the International...

2013-08-29 23:30:41

Media health report cites problems with prescribing of antibiotics such as Zithromax by physicians. Resource4thePeople announces it will continue to provide free legal consultations about rights to legal compensation over allegations of dangerous side effects from the use of Zithromax and Zmax SR. San Diego, CA (PRWEB) August 29, 2013 http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html Resource4thePeople announced today its latest update for consumers keeping abreast...

2013-08-20 08:29:22

Single administration of sustained-release antibiotic demonstrated clinically meaningful reduction in post-operative treatment failure SAN DIEGO, Aug. 20, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive results from a Phase 1b study of OTO-201 in pediatric patients undergoing tympanostomy tube placement (TTP) surgery. OTO-201 is Otonomy's...

2013-05-16 00:20:56

TAIPEI, Taiwan, May 16, 2013 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they have submitted New Drug Application (NDA) for the oral formulation of nemonoxacin with the Taiwan Food and Drug Administration (TFDA) and China Food and Drug Administration (CFDA). Approval is expected in the first half of 2014. Nemonoxacin is the first pharmaceutical product to fall under the Cross-Strait Cooperation Agreement on Medicine and Public Health Affairs of the...


Latest Ofloxacin Reference Libraries

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (1 articles) »